Day One Wednesday, October 21 Day Two Thursday, October 22 9am-3pm EST | 6am-12pm PDT | 2pm-8pm GMT Day 2 : Thursday | October 22 8:15 am Registration & Coffee Room Opens 8:45 am Chair’s Opening Remarks George Goldsmith CEO & Cofounder, COMPASS Pathways 9:00 am Delivering MDMA Therapy for Treatment of Alcoholism and Discussing Lessons Learnt to Develop Clinical Best Practice Ben Sessa Chief Medical Officer, AWAKN Life Sciences 9:30 am Dismantling barriers to clinical psychedelic research: Addressing the UK’s unmet mental health treatment needs Crispin Blunt Chair of the Foreign Affairs Select Committee, Conservative Party UK 10:00 am NOVEL DATA: Microdosing – Effects Beyond Placebo? David Erritzoe Clinical Director, Center for Psychedelic Research, Imperial College London 10:30 am Panel Discussion: Next Steps in Clinical Development of Psychedelic Therapies and Developing Industry Best Practice Ben Sessa Chief Medical Officer, AWAKN Life Sciences Roger McIntyre CEO, Champignon Brands Shlomi Raz CEO, Eleusis Ltd. Corine De Boer Chief Medical Officer, MAPS PBC 11:15 am Morning Refreshments & Poster Session 12:00 pm Proposing Best Practice in Psychedelic Drug Administration for Optimal Patient Care and Therapeutic Success Roger McIntyre CEO, Champignon Brands 12:30 pm Developing Clinical Infrastructure and Addressing Administration Challenges with Psychedelic Drugs Corine De Boer Chief Medical Officer, MAPS PBC 1:00 pm Mastermind Session: Creating and Contrasting Strategies to Make Psychedelic Therapies More Affordable Rick Doblin Founder & Executive Director, MAPS George Goldsmith CEO & Cofounder, COMPASS Pathways Srinivas Rao CSO, ATAI Life Science 1:45 pm Chair’s Closing Remarks George Goldsmith CEO & Cofounder, COMPASS Pathways 2:00 pm Late Lunch Networking 3:00 pm Close of Day 2 DAY ONE